Lapatinib (Tykerb), a tyrosine kinase inhibitor, targets the ATP binding pocket of the kinase domain of EGFR and HER2 and has been used as an alternative treatment of HER2-positive breast cancer patients that developed resistance to Trastuzumab [8,9]. This evidence concerns the gene ERBB2 and breast cancer.